HC Wainwright Issues Pessimistic Estimate for ELVN Earnings

Enliven Therapeutics, Inc. (NASDAQ:ELVN) – Analysts at HC Wainwright lowered their Q1 2026 EPS estimates for shares of Enliven Therapeutics in a research note issued on Thursday, March 26th. HC Wainwright analyst R. Burns now expects that the company will post earnings per share of ($0.44) for the quarter, down from their previous estimate of ($0.43). HC Wainwright has a “Buy” rating and a $56.00 price objective on the stock. The consensus estimate for Enliven Therapeutics’ current full-year earnings is ($1.95) per share. HC Wainwright also issued estimates for Enliven Therapeutics’ Q2 2026 earnings at ($0.48) EPS, Q3 2026 earnings at ($0.52) EPS and FY2026 earnings at ($2.00) EPS.

Several other equities research analysts have also recently commented on ELVN. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Wednesday, January 21st. Mizuho upped their target price on Enliven Therapeutics from $41.00 to $45.00 and gave the stock an “outperform” rating in a research report on Wednesday, March 25th. Finally, Wall Street Zen cut shares of Enliven Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 28th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $43.40.

Enliven Therapeutics Trading Up 7.1%

Shares of ELVN opened at $39.20 on Monday. The firm’s fifty day simple moving average is $29.00 and its two-hundred day simple moving average is $23.27. Enliven Therapeutics has a 12 month low of $13.30 and a 12 month high of $40.62. The stock has a market capitalization of $2.34 billion, a P/E ratio of -21.08 and a beta of 0.33.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.06).

Hedge Funds Weigh In On Enliven Therapeutics

Several institutional investors have recently bought and sold shares of the company. Affinity Asset Advisors LLC purchased a new position in shares of Enliven Therapeutics during the 2nd quarter valued at $8,024,000. Candriam S.C.A. increased its stake in shares of Enliven Therapeutics by 46.3% in the third quarter. Candriam S.C.A. now owns 609,352 shares of the company’s stock worth $12,473,000 after purchasing an additional 192,702 shares in the last quarter. HighVista Strategies LLC boosted its holdings in Enliven Therapeutics by 83.1% in the 3rd quarter. HighVista Strategies LLC now owns 259,135 shares of the company’s stock worth $5,304,000 after buying an additional 117,619 shares during the period. Geode Capital Management LLC grew its stake in Enliven Therapeutics by 7.8% in the 2nd quarter. Geode Capital Management LLC now owns 882,753 shares of the company’s stock valued at $17,711,000 after buying an additional 63,580 shares in the last quarter. Finally, Franklin Resources Inc. grew its stake in Enliven Therapeutics by 2,029.3% in the 2nd quarter. Franklin Resources Inc. now owns 430,240 shares of the company’s stock valued at $8,631,000 after buying an additional 410,034 shares in the last quarter. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Insider Activity

In other news, COO Anish Patel sold 48,300 shares of Enliven Therapeutics stock in a transaction on Friday, January 9th. The stock was sold at an average price of $27.99, for a total transaction of $1,351,917.00. Following the sale, the chief operating officer directly owned 215,011 shares in the company, valued at $6,018,157.89. The trade was a 18.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Richard A. Heyman sold 1,230 shares of Enliven Therapeutics stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $26.18, for a total value of $32,201.40. Following the sale, the director owned 22,647 shares in the company, valued at $592,898.46. The trade was a 5.15% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 232,180 shares of company stock worth $6,217,033. Corporate insiders own 25.90% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.